香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 變更聯席公司秘書 及 豁免嚴格遵守 上市規則第3.28條及第8.17條 聯席公司秘書辭任 廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）謹此宣佈，金今女士（「金女士」）因個人發展原因辭任本 公司聯席公司秘書（「聯席公司秘書」），自2026年2月6日起生效。 金女士已確認，彼與董事會並無意見分歧，亦無與其辭任有關的事宜需提請香港 聯合交易所有限公司（「聯交所」）或本公司股東（「股東」）垂注。董事會亦不知悉 與其辭任有關須提請股東及聯交所垂注的其他事宜。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 施女士在聯交所主板上市公司的企業管治及公司秘書常規方面擁有逾15年經驗。 施女士為特許秘書、特許企業管治專業 ...

Core Viewpoint - The company, Yinnuo Pharmaceutical-B, has seen a significant stock price increase following the announcement of its clinical trial application for a new veterinary drug aimed at treating diabetes in pets, indicating strong market interest and potential growth in the pet pharmaceutical sector [1] Group 1: Company Developments - Yinnuo Pharmaceutical-B's core product, Isupatide α, has had its clinical trial application for treating pet diabetes officially accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The company plans to commence Phase I clinical trials in the first quarter of 2026, reflecting a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant prospects, as pet owners are increasingly willing to invest in extending their pets' lifespans [1] Group 2: Regulatory Compliance and Research Progress - The company has adhered to all regulatory standards and requirements related to veterinary drug research and registration set by the Ministry of Agriculture [1] - Yinnuo Pharmaceutical-B has successfully completed relevant preclinical trials, showing positive results in efficacy and safety for Isupatide α in managing pet diabetes [1] - The positive outcomes from preclinical trials provide a solid basis for the subsequent clinical trials and registration applications for the drug [1]

Core Viewpoint - Silver诺医药-B's stock surged over 17% following the announcement of its clinical trial application for a new veterinary drug aimed at treating diabetes in pets, which has been officially accepted by the Ministry of Agriculture and Rural Affairs of China [1] Group 1: Company Developments - The company announced that its core product, Isu-Paglutide α, is set to enter Phase I clinical trials for treating pet diabetes, expected to commence in the first quarter of 2026 [1] - The board believes that developing diabetes medication for pets presents significant market potential, as pet owners are increasingly willing to invest in extending their pets' lifespans [1] - The company has complied with all regulatory standards and successfully completed the necessary preclinical trials, showing positive results in efficacy and safety for managing diabetes in pets [1]

Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isu-Paglutide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isu-Paglutide α, is intended for the treatment of diabetes in pets [1] - The company has successfully completed all preclinical trials and met the regulatory standards set by the Ministry of Agriculture and Rural Affairs [1] - Positive results regarding efficacy and safety from preclinical trials provide a reasonable basis for subsequent clinical trials and registration applications [1] Group 2: Market Potential - The board believes that developing diabetes medications for pets has significant market potential due to increasing consumer willingness to spend on extending the lifespan of pets [1] - This research aligns with the company's long-term business development strategy and will lay a solid foundation for entering the pet pharmaceuticals market [1]

Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isupatide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isupatide α, is intended for the treatment of diabetes in pets, indicating a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant potential due to increasing consumer willingness to spend on extending pet lifespans [1] Group 2: Regulatory Compliance - The company has complied with all relevant standards and regulatory requirements for veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has been achieved, demonstrating positive progress in efficacy and safety for Isupatide α in managing pet diabetes [1]

Core Viewpoint - Silver诺医药-B (02591.HK) has received formal acceptance from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its clinical trial application of its core product, Isu-Paglutide α, for the treatment of diabetes in pets, with Phase I trials expected to commence in the first quarter of 2026 [1] Group 1: Product Development - The company believes that the development of diabetes medication for pets has significant potential due to increasing consumer willingness to invest in extending the lifespan of their pets [1] - The board views this research and development as aligned with the company's long-term business development strategy, laying a solid foundation for future entry into the pet pharmaceuticals market [1] Group 2: Regulatory Compliance and Trial Progress - The company has complied with all standards and regulatory requirements related to veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has shown positive progress in terms of efficacy and safety for Isu-Paglutide α in managing pet diabetes, providing a reasonable basis for subsequent clinical trials and registration applications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 自願性公告 依蘇帕格魯肽α的新獸藥臨床試驗申請獲受理 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東（「股東」）及有意投資者提供有關本公司業務最 新進展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年2月4日，本公司核心產 品依蘇帕格魯肽α用於治療寵物糖尿病的新獸藥臨床試驗申請已獲中華人民共和 國農業農村部（「農業部」）正式受理。預計將於2026年第一季度開始I期臨床試驗。 董事會認為，研發寵物糖尿病藥物具有廣闊的前景。由於人們愈發願意接受並花 費金錢延長寵物的壽命，董事會認為，此類研發符合本集團的長期業務發展策 略，並將為本集團未來 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | ...

Core Insights - The J.P. Morgan Healthcare Conference highlighted the weight loss market as a key focus, with major pharmaceutical companies like Eli Lilly, Novo Nordisk, and Pfizer emphasizing their commitment to this sector [1] - Pfizer plans to launch weight loss assets acquired from Metzera by mid-2028, indicating a long-term strategy in the weight loss market [1] - Eli Lilly's Orforglipron has been submitted for approval in China, following its inclusion in the FDA's expedited approval list in November 2025 [1] Pricing Strategies - Novo Nordisk announced a significantly lower price for its oral version of semaglutide (Wegovy) compared to its injectable counterpart, with monthly costs starting at approximately $149 for self-paying patients [2] - The price of injectable semaglutide (Ozempic) was previously set at $969 per month, while Wegovy was priced at $1,349 per month [2] - Agreements with the U.S. government will lead to price reductions for semaglutide and Orforglipron starting in 2026, with some products capped at $50 per month [3] Market Competition - The GLP-1 market is experiencing intense competition, with 88 small molecule GLP-1 drugs currently in development, including six in Phase III trials [3] - A price war has erupted in the GLP-1 injection market, driven by increased supply and the expiration of patents for key products [4] - The introduction of new competitors and the expansion of indications for GLP-1 drugs are reshaping the market landscape [5] Domestic Market Dynamics - The new national medical insurance directory in China has initiated a price competition era for GLP-1 products, with significant discounts being offered on e-commerce platforms [4][6] - The price of semaglutide and other competing products has seen drastic reductions, with some prices dropping to as low as 20% of their original costs [5][6] - The entry of multiple domestic companies into the GLP-1 market is intensifying the price competition, particularly as patents expire [9][19] Future Outlook - The GLP-1 market is expected to grow significantly, with projections indicating a potential market size exceeding $100 billion by 2030 [16] - The competition is shifting from price-based to innovation-based, focusing on multi-target therapies and expanded indications [16] - The expiration of key patents is likely to lead to an influx of generic competitors, further intensifying the price competition [17][19]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州銀諾醫藥集團股份有限公司（於中華人民共和國成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 ...